Stallergenes Greer Announces Global Agreement With Nestlé Regarding the Peanut Allergy Oral Immunotherapy Treatment Palforzia®
Stallergenes Greer, a leading global healthcare company specialising in allergen immunotherapy (AIT), announced today that it has signed global agreements with Nestlé to harness the peanut allergy oral immunotherapy treatment Palforzia®. The transaction was closed upon signing.
Peanut allergy currently affects approximately 2% of the general population of Western nations1, and the prevalence of peanut allergy doubled among children between 2005 and 20152. The difficulty of avoiding peanuts, combined with the severity of allergic reactions, including anaphylaxis, shows the need for effective treatment3.
“We are delighted about this agreement with Nestlé which marks a significant milestone for Stallergenes Greer,” stated Michele Antonelli, CEO of Stallergenes Greer. “Palforzia®, with its robust efficacy and safety profile, is currently the only available approved treatment for inadvertent exposure to peanuts. By entering the food allergy space, Stallergenes Greer becomes the first allergen immunotherapy company to offer both respiratory and food allergy treatments and demonstrates its lasting commitment to provide patients and the medical community with innovative allergen immunotherapy treatments.”
Nestlé will receive milestone payments and ongoing royalties from Stallergenes Greer. There will be a customary transition period to ensure business continuity and give patients uninterrupted access to the treatment.
With this transaction, Stallergenes Greer further strengthens its presence in the field of AIT. The company’s portfolio offers patients and healthcare professionals precise personalised AIT treatments which cover a broad range of administration modes and can be tailored to the individual needs of patients with allergies: sublingual oral solutions, tablets, and injectables for respiratory allergies; and powder to be consumed with semi-solid foods for peanut allergies.
ABOUT PALFORZIA ®
Palforzia® is an oral immunotherapy treatment approved for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut for patients aged 4 to 17 years with a confirmed diagnosis of peanut allergy by the U.S. Food and Drug Administration (FDA), the European Commission (EC), the Medicines and Healthcare products Regulatory Agency (MHRA) in the U.K., and by Swissmedic. Use of Palforzia® may be continued in patients 18 years of age and older.
Palforzia® is not indicated for the emergency treatment of allergic reactions, including anaphylaxis, and must always be used in conjunction with a peanut-avoidant diet.
ABOUT STALLERGENES GREER INTERNATIONAL AG
Headquartered in Baar (Switzerland), Stallergenes Greer International AG is a global healthcare company specialising in the diagnosis and treatment of allergies through the research, development and commercialisation of allergen immunotherapy products and services. Stallergenes Greer International AG is the parent company of Greer Laboratories, Inc. (whose registered office is in the United States) and Stallergenes SAS (whose registered office is in France). For more information, visit www.stallergenesgreer.com.
1 The global burden of illness of peanut allergy: A comprehensive literature review. Jay A. Lieberman, Ruchi S Gupta, Rebecca C. Knibb, Tmirah Haselkorn, Stephen Tilles, Douglas P. Mack, and Guillaume Pouessel. Online: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247890/. Accessed August 31, 2023
2 Du Toit G, et al. Randomized Trial of Peanut Consumption in Infants at Risk for Peanut Allergy. N Engl J Med 2015; 372: 803-13. Accessed August 31, 2023.
3 Bock SA, Muñoz-Furlong A, Sampson HA. Fatalities due to anaphylactic reactions to foods. J Allergy Clin Immunol. 2001;107:191-3. Accessed August 31, 2023.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230903080283/en/
Contact information
Stallergenes Greer
Communications
Catherine Kress
Tel: +33 (0)1 55 50 26 05
Email: catherine.kress@stallergenesgreer.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KILL TOURISE and Globant Unveil Game-Changing Report on Agentic Tourism that Sets New Standards for AI-Driven Destination Innovation23.10.2025 11:30:00 EEST | Press release
TOURISE requests that their press release NewsItemID: 20251022347041 “TOURISE and Globant Unveil Game-Changing Report on Agentic Tourism that Sets New Standards for AI-Driven Destination Innovation” be killed. The release was issued in error by TOURISE. A replacement release will be issued on October 23.
Vodafone Spain and Twilio Partner to Offer Secure and Interactive RCS Messaging to Businesses in Spain23.10.2025 11:00:00 EEST | Press release
Twilio, the customer engagement platform that powers personalised, real-time experiences for today's leading brands, has announced an extended partnership with Vodafone Spain, one of the country's leading telecommunications operators. This will enable Spanish businesses to access Rich Communication Services (RCS) messaging, revolutionising the way they interact with their customers through rich, interactive and secure communications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251023623745/en/ Vodafone Spain has relied on Twilio's global expertise to accelerate the adoption of this next-generation messaging solution, positioning it as the new standard for business communication in the Spanish market. A much needed evolution for mobile communication In a world where personalisation and trust are essential for brand to consumer relationships, RCS offers an experience that goes beyond the capabilities of traditional SMS. Acc
TOURISE and Globant Unveil Game-Changing Report on Agentic Tourism that Sets New Standards for AI-Driven Destination Innovation23.10.2025 09:01:00 EEST | Press release
Imagine a traveler’s perfect day planning itself, rerouting around a rainstorm, prompting a café to add staff before the lunch rush, suggesting a quiet gallery when crowds swell. This is the promise of Agentic Tourism, an AI-powered operating model introduced in a new white paper by TOURISE and Globant, a digitally native company that helps organizations thrive in a digital and AI-powered future, with strategic contribution from Kearney. The report, titled Tourism’s AI Takeover: Reinventing Travel through Agentic Tourism, presents a practical framework for transforming the tourism experience making it more seamless, intelligent, and emotionally resonant. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022347041/en/ TOURISE and Globant Unveil New White Paper on Agentic AI in Tourism In 2024, tourism generated 10.9 trillion dollars, nearly 10 percent of global GDP, and is projected to reach 16.5 trillion dollars by 2035. AI
Bureau Veritas: Robust and Consistent Revenue Performance Delivered in Q3 2025; FY 2025 Outlook Reaffirmed23.10.2025 08:30:00 EEST | Press release
Bureau Veritas (BOURSE:BVI): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022995674/en/ Hinda Gharbi, CEO Bureau Veritas Q3 2025 Key figures1 › Revenue of EUR 1,583.7 million, up 2.3% year-on-year and up 6.3% organically › A very strong organic growth from Marine & Offshore at 16.2%; solid recovery of Buildings & Infrastructure at 7.1% organically; strong organic growth maintained for both Industry and Certification, at 6.9% and 5.9% respectively, against challenging comparables; moderate organic growth for Consumer Products Services at 3.5% and Agri-Food & Commodities at 2.5% › Positive scope effect of 0.8%, from the accelerated pace of bolt-on acquisitions (+3.1% contribution) realized, net of disposals (-2.3% contribution) › Negative currency impact of 4.8%, resulting from the euro’s appreciation against most currencies Q3 2025 Highlights › Continued progress in implementing the LEAP I 28 strategy, delivering results
Bureau Veritas Accelerating Its LEAP | 28 Strategy With Two Signed Agreements for Acquisitions in Buildings & Infrastructure and Renewables23.10.2025 08:20:00 EEST | Press release
Bureau Veritas, a global leader in Testing, Inspection, and Certification (TIC) services, announces that it has signed agreements to acquire two companies in Europe, reinforcing its leading position and expanding into high-potential markets: Sólida in the renewables sector, and London Building Control in the Buildings & Infrastructure market. These agreements underscore Bureau Veritas’ commitment to growth within its LEAP I 28 strategy, increasing capability, reach, and technical expertise across growth markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022071543/en/ Hinda Gharbi, CEO Bureau Veritas Sólida is a top-tier provider of Owner’s Engineering, Technical Advisory, and Project Management services for renewable energy projects and electrical infrastructure. It acts as a trusted technical partner for leading developers, utilities, EPC contractors, investment funds and financial institutions. The Company has demo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom